{"product_id":"alnylam-pestle-analysis","title":"Alnylam PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, reimbursement dynamics, and rapid biotech innovation are shaping Alnylam’s trajectory—our concise PESTLE snapshot highlights key risks and opportunities that matter to investors and strategists. Purchase the full PESTLE to unlock detailed regulatory, economic, social, technological, legal, and environmental analysis tailored for actionable decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of the Inflation Reduction Act\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe IRA's drug price negotiation program, active from 2023, poses direct revenue risk to Alnylam as CMS targets high-spend drugs; negotiated price caps could reduce peak U.S. orphan-drug revenues—Alnylam's 2024 U.S. product sales were $1.2B, highlighting exposure. As of late 2025, the Small Biotech Exception's criteria and duration will determine whether Alnylam's expanding RNAi portfolio qualifies, affecting forecasted CAGR and discounted cash flow assumptions. This political change forces reassessment of long-term U.S. pricing strategies for RNAi therapies, potentially lowering price elasticity estimates and revenue per patient used in valuation models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal healthcare trade policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing trade tensions and rising protectionism in markets like China and the EU—where goods tariffs rose by 4% on average between 2019–2023—complicate distribution and manufacturing logistics for Alnylam’s rare-disease siRNA therapies, potentially increasing COGS and time-to-market.\u003c\/p\u003e\n\u003cp\u003ePolitical stability in these regions affects market entry and IP security for Alnylam’s RNAi platform; China recorded 12% of global pharma M\u0026amp;A volume in 2024, underscoring strategic importance and IP risk exposure.\u003c\/p\u003e\n\u003cp\u003eAlnylam must monitor diplomatic relations and regulatory shifts to mitigate supply-chain disruption risks and localized manufacturing demands, given that 30–40% of active pharmaceutical ingredient sourcing remains concentrated in Asia as of 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment funding for rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical backing for orphan drug incentives like the US Orphan Drug Act and EU orphan designation remains vital for Alnylam, guiding its decision to allocate over $1.6bn in R\u0026amp;D in 2024 toward RNAi CNS and ocular programs.\u003c\/p\u003e\n\u003cp\u003eAny shift in subsidy priorities—e.g., US NIH rare disease funding dropping 2.7% in 2023—could delay costly Phase II\/III trials, impacting timelines and potential revenue from projected peak sales of $4–6bn for lead assets.\u003c\/p\u003e\n\u003cp\u003eMaintaining strong ties with policymakers and regulators helps secure grants, tax credits and accelerated pathways that mitigate the high-cost, long-duration development cycles of genomic medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory agency leadership shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanges in FDA and EMA leadership shift approval speed and safety focus; under new leaders since 2024, review timelines for novel biologics varied by ±20% in median review time across EU\/US in 2024–25, affecting Alnylam's launch pacing.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Alnylam must align with frameworks favoring real-world evidence and accelerated pathways for RNAi; 2024 saw a 35% rise in expedited pathway submissions for gene therapies.\u003c\/p\u003e\n\u003cp\u003ePolitical appointments alter agencies' risk appetite, influencing post-market surveillance demands and potential label restrictions that could impact Alnylam's revenue timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedian regulatory review variance ±20% (2024–25)\u003c\/li\u003e\n\u003cli\u003e35% increase in expedited submissions for gene therapies (2024)\u003c\/li\u003e\n\u003cli\u003eEnd-2025 shift toward real-world evidence\/accelerated pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health infrastructure investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment investment in genetic diagnostic infrastructure boosts identification of candidates for Alnylam’s RNAi therapies; expanded newborn screening initiatives in the US and EU—some programs increasing tested conditions by 20–40% since 2020—can enlarge Alnylam’s addressable hereditary disease market.\u003c\/p\u003e\n\u003cp\u003ePolitical moves to reimburse genetic testing (e.g., CMS coverage updates) improve uptake and revenue potential, while public health budget cuts—2024 WHO data shows constrained genomics funding in several low\/mid-income countries—risk diagnostic bottlenecks and delayed treatment starts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpanded newborn\/genetic screening +20–40% testing scope since 2020 increases eligible patient identification\u003c\/li\u003e\n\u003cli\u003eReimbursement policy changes (CMS, EU national programs) raise test uptake and therapy revenue potential\u003c\/li\u003e\n\u003cli\u003ePublic health budget cuts (2024 WHO reports) create diagnosis\/treatment access bottlenecks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIRA risks $1.2B U.S. peak sales; small-biotech status, tariffs, supply and review volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIRA negotiation risks U.S. peak revenues (2024 U.S. sales $1.2B); Small Biotech Exception status by late-2025 will affect valuation; trade tensions and 4% tariff rise (2019–23) raise COGS; 30–40% API sourcing in Asia (2025) heightens supply risk; orphan incentives and $1.6B R\u0026amp;D (2024) funding depend on policy; FDA\/EMA review variance ±20% (2024–25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI sourcing (2025)\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory review variance (2024–25)\u003c\/td\u003e\n\u003ctd\u003e±20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff rise (2019–23)\u003c\/td\u003e\n\u003ctd\u003e+4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Alnylam across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Alnylam that’s easy to drop into presentations or planning sessions, helping teams quickly assess external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh cost of RNAi therapy production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe specialized manufacturing for lipid nanoparticles and GalNAc conjugates requires heavy capital investment and complex supply chains; Alnylam reported 2024 R\u0026amp;D and manufacturing capex of about $725 million, reflecting this intensity. Economic swings in raw material prices and skilled labor affect gross margins—Onpattro and Amvuttra faced combined gross margin pressure with reported 2024 product gross margin near 48%. Alnylam is pursuing economies of scale as it expands into larger indications like hypertension, projecting potential addressable market expansion from ~$1.5B in rare disease sales to multi‑billion dollar opportunities in cardiovascular indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal interest rate environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, global policy rates remain elevated—US Fed funds at 5.25–5.50% and ECB deposit at 4.00%—lifting discount rates and compressing valuations for growth biotechs like Alnylam; a 100 bp rise can cut present value of long‑dated pipeline cash flows materially. Higher rates raise Alnylam’s weighted average cost of capital, pressuring investor sentiment and making equity financing pricier for RNAi R\u0026amp;D. The firm must manage modest net debt (~$1.2bn end‑2024) while maintaining \u0026gt;20% reinvestment in clinical programs to sustain pipeline momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith roughly 40% of Alnylam’s 2024 revenue derived from international markets, volatility in USD\/EUR and USD\/JPY can materially impact reported sales; a 5% dollar appreciation would cut translated Euro\/Yen revenues by about 5%. Economic turbulence in Europe and Japan during 2024–25 increased FX pressure, contributing to quarterly swings in top-line figures. Alnylam employs hedging instruments and localized financial planning to mitigate translation risk and protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement and affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe high cost of Alnylam’s RNAi therapies pressures payers toward value-based contracts; global gene-silencing launches often list at \u0026gt;$450,000\/year (for reference, Onpattro pricing historically ~$450k), pushing insurers to tie reimbursement to outcomes.\u003c\/p\u003e\n\u003cp\u003ePayers demand evidence Alnylam’s products deliver superior QALY gains versus small molecules to justify premiums; HTA agencies in UK\/NICE and Germany\/G-BA increasingly require cost-effectiveness thresholds (~£20–30k\/QALY in NICE discussions) and real-world outcomes.\u003c\/p\u003e\n\u003cp\u003eConstrained public budgets—OECD health spending growth slowed to ~2%–3% annually in recent years—drive stricter assessments and potential price caps or mandatory discounts, raising launch access risks in key markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eList prices often \u0026gt;$400k–$500k\/year; outcome-based contracts increasing\u003c\/li\u003e\n\u003cli\u003eHTA thresholds and QALY evidence pivotal for reimbursement\u003c\/li\u003e\n\u003cli\u003eOECD budget pressure and slowdown (~2–3% growth) heighten price negotiations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket expansion into emerging economies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic growth in Southeast Asia (projected GDP growth ~4.5% in 2025) and Latin America (estimated ~2.6% in 2025) opens demand for Alnylam’s hepatic and cardio-metabolic therapies, but lower per-capita health spend (e.g., SEA ~$400–$1,200; LATAM ~$500–$2,000) necessitates flexible pricing, tiered access, and partnerships to leverage rising middle-class populations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGDP growth: SEA ~4.5% (2025 est), LATAM ~2.6% (2025 est)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capex, heavy debt and margin pressure heighten valuation risk for RNAi therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCapital‑intensive RNAi production (2024 capex ~$725M) and ~48% product gross margin pressure; net debt ~ $1.2B (end‑2024) with \u0026gt;20% reinvestment in R\u0026amp;D. Elevated rates (Fed 5.25–5.50%, ECB 4.00% late‑2025) raise WACC and valuation risk. FX volatility (40% revenue international) and payer pressure push outcome‑based pricing for therapies often priced ~$400k–$500k\/year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/manuf capex\u003c\/td\u003e\n\u003ctd\u003e$725M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct gross margin\u003c\/td\u003e\n\u003ctd\u003e~48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlnylam PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Alnylam PESTLE document you’ll receive after purchase—fully formatted and ready to use, with complete political, economic, social, technological, legal, and environmental analysis tailored to Alnylam.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751872409977,"sku":"alnylam-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alnylam-pestle-analysis.png?v=1772235612","url":"https:\/\/growthsharematrix.com\/products\/alnylam-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}